全球生物相似藥市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計生物相似藥市場將從 2025 年的 397.3 億美元成長到 2034 年的 1,529.7 億美元，2026 年至 2034 年的複合年成長率為 16.16%。

生物相似藥市場正進入關鍵成長階段，其驅動力來自生物製藥專利到期以及監管機構對具成本效益替代藥物日益成長的支持。未來生物相似藥的研發將充分利用先進的細胞株設計、製程最佳化和人工智慧驅動的預測模型，以確保產品品質、療效和安全性的一致性。與藥物監測平台和即時批次分析的整合將加速監管核准和市場上市進程。

新興的生物製程技術，例如連續生產、高產量上游工程和精密純化技術，能夠降低生產成本並提高可擴展性。人工智慧輔助的臨床試驗設計和患者分層縮短了研發週期，同時增強了療效評估。與數位健康平台的整合實現了對治療結果和不利事件的即時監測。

未來市場成長將受到醫療保健產業成本控制、全球生物製藥的需求以及精準醫療策略應用等因素的驅動。透過結合製程創新、監管資訊和數位化監測，生物相似藥將擴大救命生物製藥的可及性，從而在全球範圍內提高其可負擔性和療效。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球生物相似藥市場：依產品分類

• 市場分析、洞察與預測
• 重組非糖基化蛋白
• 重組糖基化蛋白

第5章 全球生物相似藥市場：依應用領域分類

• 市場分析、洞察與預測
• 腫瘤學
• 血液疾病
• 生長激素缺乏症
• 類風濕性關節炎
• 慢性疾病與自體免疫疾病
• 其他

第6章 全球生物相似藥市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第7章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第8章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Amgen Inc
  • F Hoffman-La Roche Ltd
  • Sandoz International GmbH
  • Dr. Reddy'S Laboratories Ltd
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Samsung Biopis
  • Biocon
  • Viatris Inc
  • Celltrion Healthcare Co. Ltd
  • AbbVie Inc

The Biosimilars Market size is expected to reach USD 152.97 Billion in 2034 from USD 39.73 Billion (2025) growing at a CAGR of 16.16% during 2026-2034.

The biosimilars market is entering a critical growth phase as patent expirations of biologics and regulatory support for cost-effective alternatives expand. Future biosimilar development will leverage advanced cell line engineering, process optimization, and AI-driven predictive modeling to ensure consistent quality, efficacy, and safety. Integration with pharmacovigilance platforms and real-time batch analytics will accelerate regulatory approval and market readiness.

Emerging bioprocessing innovations, including continuous manufacturing, high-yield upstream processing, and precision purification technologies, will reduce production costs and improve scalability. AI-assisted clinical trial design and patient stratification will enhance efficacy evaluation while shortening development timelines. Integration with digital health platforms will enable real-time monitoring of treatment outcomes and adverse events.

Future market growth will be driven by healthcare cost containment, global biologics demand, and adoption of precision medicine strategies. By combining process innovation, regulatory intelligence, and digital monitoring, biosimilars will expand access to life-saving biologics, enhancing affordability and treatment efficacy worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Recombinant Non-glycosylated Proteins
• Recombinant Glycosylated Proteins

By Application

• Oncology
• Blood Disorders
• Growth Hormonal Deficiency
• Rheumatoid Arthritis
• Chronic and Autoimmune Disorders
• Others

COMPANIES PROFILED

• Amgen Inc, F HoffmanLa Roche Ltd, Sandoz International GmbH, Dr Reddys Laboratories Ltd, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Biopis, Biocon, Viatris Inc, Celltrion Healthcare Co Ltd, AbbVie Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOSIMILARS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Recombinant Non-glycosylated Proteins Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Recombinant Glycosylated Proteins Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOSIMILARS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Blood Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Growth Hormonal Deficiency Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Rheumatoid Arthritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Chronic and Autoimmune Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOSIMILARS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product
  • 6.2.2 By Application
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product
  • 6.3.2 By Application
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product
  • 6.4.2 By Application
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product
  • 6.5.2 By Application
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product
  • 6.6.2 By Application
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL BIOSIMILARS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Amgen Inc
  • 8.2.2 F Hoffman-La Roche Ltd
  • 8.2.3 Sandoz International GmbH
  • 8.2.4 Dr. Reddy'S Laboratories Ltd
  • 8.2.5 Teva Pharmaceutical Industries Ltd
  • 8.2.6 Pfizer Inc
  • 8.2.7 Samsung Biopis
  • 8.2.8 Biocon
  • 8.2.9 Viatris Inc
  • 8.2.10 Celltrion Healthcare Co. Ltd
  • 8.2.11 AbbVie Inc